Explore the categories so you can find more about your search.

Categorie > Blood / Hematology

ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting

Categorie : Blood / Hematology
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced that it presented positive data from a phase II study of darinaparsin, the Company's novel organic arsenic compound, in advanced hematological malignancies at the American Association for Cancer Research (AACR) Annual Meeting, in San Diego, CA. ...

read more ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced that it presented positive data from a phase II study of darinaparsin, the Company's novel organic arsenic compound, in advanced hematological malignancies at the American Association for Cancer Research (AACR) Annual Meeting, in San Diego, CA. read more Sat Apr 2008 Sat Apr 2008

Anticoagulant Therapy Supply SOP Produced By The NPA, UK

Categorie : Blood / Hematology
The NPA has produced a resource for the supply of anticoagulant therapy comprising of a template standard operating procedure (SOP) and guidance notes. It complies with the NPSA recommendations ensuring the supply of anticoagulant medicines is carried out in a safe and efficient way.'Supplying Antic ...

read more The NPA has produced a resource for the supply of anticoagulant therapy comprising of a template standard operating procedure (SOP) and guidance notes. It complies with the NPSA recommendations ensuring the supply of anticoagulant medicines is carried out in a safe and efficient way.'Supplying Antic read more Sat Apr 2008 Sat Apr 2008

Global Bleeding Disorders Community Campaigns To Diagnose At-Risk Patients

Categorie : Blood / Hematology
No person should have to endure the pain and suffering caused by hemophilia, a rare bleeding disorder that causes dangerous internal bleeding. There are about 400,000 people with hemophilia worldwide, according to the World Federation of Hemophilia, but only about 30% have been diagnosed. April 17 i ...

read more No person should have to endure the pain and suffering caused by hemophilia, a rare bleeding disorder that causes dangerous internal bleeding. There are about 400,000 people with hemophilia worldwide, according to the World Federation of Hemophilia, but only about 30% have been diagnosed. April 17 i read more Sat Apr 2008 Sat Apr 2008

Global Blood Banking And Blood Products Market To Reach 31.7 Billion Dollars By 2010, According To New Report By Global Industry Analysts, Inc.

Categorie : Blood / Hematology
A spurt in new infections surfacing the world over remains a huge concern to the blood banking and blood products industry. Though awareness amongst the consumers, and health workers helped in reducing the intensity of infection, the industry is yet to free itself of the various problems such as saf ...

read more A spurt in new infections surfacing the world over remains a huge concern to the blood banking and blood products industry. Though awareness amongst the consumers, and health workers helped in reducing the intensity of infection, the industry is yet to free itself of the various problems such as saf read more Sat Apr 2008 Sat Apr 2008

Cytopia Nominates JAK2 Clinical Candidate For Myeloproliferative Disorders - Clinical Study To Commence Late This Year

Categorie : Blood / Hematology
Cytopia Limited (ASX:CYT) has selected CYT387, a selective and potent JAK2 inhibitor, for formal preclinical development to treat myeloproliferative disorders (MPDs). This follows extensive laboratory experimentation and includes the recent demonstration of activity in an in-vivo model of myeloprol ...

read more Cytopia Limited (ASX:CYT) has selected CYT387, a selective and potent JAK2 inhibitor, for formal preclinical development to treat myeloproliferative disorders (MPDs). This follows extensive laboratory experimentation and includes the recent demonstration of activity in an in-vivo model of myeloprol read more Tue Mar 2008 Tue Mar 2008

Blood Disease Protects Against Malaria In An Unexpected Way

Categorie : Blood / Hematology
Children with an inherited blood disorder called alpha thalassemia make unusually small red blood cells that mostly cause a mild form of anemia. Now, researchers have discovered that this disorder has a benefit it can protect children against one of the world's greatest killers, malaria, according t ...

read more Children with an inherited blood disorder called alpha thalassemia make unusually small red blood cells that mostly cause a mild form of anemia. Now, researchers have discovered that this disorder has a benefit it can protect children against one of the world's greatest killers, malaria, according t read more Tue Mar 2008 Tue Mar 2008

Ortho Biotech Statement On U.S. Food And Drug Administration Oncologic Drugs Advisory Committee Vote

Categorie : Blood / Hematology
Ortho Biotech is concerned by the Advisory Committee's recommendations to restrict access to erythropoiesis-stimulating agents (ESAs) for chemotherapy induced anemia (CIA) in patients with metastatic breast and head and neck cancer, and patients treated with curative intent. The company believes th ...

read more Ortho Biotech is concerned by the Advisory Committee's recommendations to restrict access to erythropoiesis-stimulating agents (ESAs) for chemotherapy induced anemia (CIA) in patients with metastatic breast and head and neck cancer, and patients treated with curative intent. The company believes th read more Mon Mar 2008 Mon Mar 2008

Failed Blood Supply Can Lead To Loose Chips In Joints

Categorie : Blood / Hematology
Osteochondrosis, or so-called "joint mice", is a very common illness of Norwegian horses, although its cause is as yet unknown. A recent Ph. D. degree by veterinary surgeon Kristin Olstad of the equine clinic of the Norwegian School of Veterinary Science concluded that failure of blood supply to the ...

read more Osteochondrosis, or so-called read more Mon Mar 2008 Mon Mar 2008

Technology Improves Odds For Critically Ill

Categorie : Blood / Hematology
Large numbers of unnecessary deaths and avoidable medical complications in intensive care units (ICU) are attributable to the difficulties of treating high glucose levels in critically ill patients' blood. That is about to change for the better thanks to a new automated insulin delivery system devel ...

read more Large numbers of unnecessary deaths and avoidable medical complications in intensive care units (ICU) are attributable to the difficulties of treating high glucose levels in critically ill patients' blood. That is about to change for the better thanks to a new automated insulin delivery system devel read more Mon Mar 2008 Mon Mar 2008

Heparin Investigation Update By Baxter

Categorie : Blood / Hematology
As reported in previous updates, Baxter's sophisticated analytical procedures, including capillary electrophoresis and nuclear magnetic resonance spectroscopy, identified an unknown material in some lots of the active pharmaceutical ingredient (API) for heparin, which is supplied to Baxter by Scient ...

read more As reported in previous updates, Baxter's sophisticated analytical procedures, including capillary electrophoresis and nuclear magnetic resonance spectroscopy, identified an unknown material in some lots of the active pharmaceutical ingredient (API) for heparin, which is supplied to Baxter by Scient read more Mon Mar 2008 Mon Mar 2008

Amicus Therapeutics Presents Positive Data From Phase 2 Clinical Trial Of Plicera(TM) For Gaucher Disease

Categorie : Blood / Hematology
Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced that the Company will present positive results from a Phase 2 clinical study of Plicera(TM) (isofagomine tartrate) for Ga ...

read more Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced that the Company will present positive results from a Phase 2 clinical study of Plicera(TM) (isofagomine tartrate) for Ga read more Mon Mar 2008 Mon Mar 2008

Publication Of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As A Standard Of Care In Multiple Myeloma Patients

Categorie : Blood / Hematology
Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced the publication of updated results of the Phase I/II clinical trial of the combination therapy VELCADE, melphalan and prednisone (VcMP) in newly diagnosed multiple myeloma patients, who were ineligible for stem cell transplantation. ...

read more Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced the publication of updated results of the Phase I/II clinical trial of the combination therapy VELCADE, melphalan and prednisone (VcMP) in newly diagnosed multiple myeloma patients, who were ineligible for stem cell transplantation. read more Mon Mar 2008 Mon Mar 2008

New Educational Effort Launched On Genetic Testing For Dosing A Common Blood Thinner

Categorie : Blood / Hematology
A new educational effort focused on improving the safety and reducing the complications of a life-saving heart drug was launched by the American Medical Association (AMA) and the Critical Path Institute (C-Path), as part of an ongoing program to support personalized medicine. ...

read more A new educational effort focused on improving the safety and reducing the complications of a life-saving heart drug was launched by the American Medical Association (AMA) and the Critical Path Institute (C-Path), as part of an ongoing program to support personalized medicine. read more Thu Mar 2008 Thu Mar 2008

Amgen To Discuss Romiplostim Application At FDA ODAC Meeting

Categorie : Blood / Hematology
Amgen Inc. (NASDAQ: AMGN) will discuss the proposed Biologic License Application (BLA) for romiplostim, an investigational thrombopoietin mimetic peptibody, for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) at the Oncologic Drugs ...

read more Amgen Inc. (NASDAQ: AMGN) will discuss the proposed Biologic License Application (BLA) for romiplostim, an investigational thrombopoietin mimetic peptibody, for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) at the Oncologic Drugs read more Thu Mar 2008 Thu Mar 2008

Amgen Statement On Successful Outcome Of Romiplostim Panel Meeting

Categorie : Blood / Hematology
Amgen Inc. (NASDAQ:AMGN) issued the following statement on the outcome of the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting on romiplostim, a investigational thrombopoietin mimetic peptibody, for the treatment of thrombocytopenia in adult patients with c ...

read more Amgen Inc. (NASDAQ:AMGN) issued the following statement on the outcome of the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting on romiplostim, a investigational thrombopoietin mimetic peptibody, for the treatment of thrombocytopenia in adult patients with c read more Thu Mar 2008 Thu Mar 2008

Heparin May Be Contaminated, Say German Authorities

Categorie : Blood / Hematology
After announcing that they suspect heparin may be contaminated, the Federal Institute for Drugs and Medical Devices, Germany, has recalled the drug thinner. This follows a withdrawal in the USA where 19 deaths have been linked to the drug. Heparin in Germany is produced by RotexMedica, part of Grou ...

read more After announcing that they suspect heparin may be contaminated, the Federal Institute for Drugs and Medical Devices, Germany, has recalled the drug thinner. This follows a withdrawal in the USA where 19 deaths have been linked to the drug. Heparin in Germany is produced by RotexMedica, part of Grou read more Wed Mar 2008 Wed Mar 2008

Some Anemia Treatment Agents Increase Risk Of Blood Clots And Death In Cancer Patients

Categorie : Blood / Hematology
Using erythropoiesis-stimulating agents (ESAs) in thetreatment of anemia increases the risk of venous thromboembolism (VTE)and death among cancer patients, according to an article in theFebruary 27, 2008 issue of JAMA.ESAs are a class of drugs that promote red blood cell production in thebody. The E ...

read more Using erythropoiesis-stimulating agents (ESAs) in thetreatment of anemia increases the risk of venous thromboembolism (VTE)and death among cancer patients, according to an article in theFebruary 27, 2008 issue of JAMA.ESAs are a class of drugs that promote red blood cell production in thebody. The E read more Wed Mar 2008 Wed Mar 2008

Blocking Fugitive Cancer Cells By Stopping Blood Cells That Aid Them

Categorie : Blood / Hematology
Cancer cells get a helping hand from platelets, specialized blood cells involved in clotting. Platelets shelter and feed tumor cells that stray into the bloodstream, making it easier for cancer to spread, or metastasize. Research at Washington University School of Medicine in St. Louis suggests that ...

read more Cancer cells get a helping hand from platelets, specialized blood cells involved in clotting. Platelets shelter and feed tumor cells that stray into the bloodstream, making it easier for cancer to spread, or metastasize. Research at Washington University School of Medicine in St. Louis suggests that read more Wed Mar 2008 Wed Mar 2008

ProMetic Reports Continued Positive Data In PBI 1402 Phase II Trial In Chemotherapy Induced Anemia

Categorie : Blood / Hematology
ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announces favorable top-line findings from the third cohort in its Phase II trial with PBI-1402 in patients with chemotherapy-induced anemia ("CIA"). Analysis of the compiled data from a total of 18 patients showed an overall statistically signific ...

read more ProMetic Life Sciences Inc. (TSX: PLI) ( read more Wed Mar 2008 Wed Mar 2008

First Early Detection Blood Test For Parkinson's Shows Promise

Categorie : Blood / Hematology
A test that profiles molecular biomarkers in blood could become the first accurate diagnostic test for Parkinson's disease, new research shows. The screen relies on changes in dozens of small molecules in serum. These "metabolomic" alterations form a unique pattern in people with Parkinson's dise ...

read more A test that profiles molecular biomarkers in blood could become the first accurate diagnostic test for Parkinson's disease, new research shows. The screen relies on changes in dozens of small molecules in serum. These read more Wed Mar 2008 Wed Mar 2008

<<< previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 next >>>



     


Custom Search